RxDoctor Payments Data

Julia Doss, APRN

Nurse Practitioner · Clarksville, TNNPI 1093340804

Payments from drug & device makers

$2,828in general payments, 2019–2025

Across 175 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$784
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$418
  • GRT US Holding, Inc.$289
  • Collegium Pharmaceutical, Inc.$278
  • Biohaven Pharmaceutical Holding Company Ltd.$164
  • Biohaven Pharmaceuticals, Inc.$155
  • plus $740 from 17 others

What the payments were for

  • Food & beverage$2,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,828 in reported general payments places this provider in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$45,892
Medicare patients
76
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate17$11,115
BelbucaBuprenorphine Hcl12$8,752
Fentanyl23$4,271
Oxycodone Hcl94$2,987
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen46$1,778
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen54$1,365
Gabapentin53$725
Promethazine Hcl11$639
Morphine Sulfate ErMorphine Sulfate22$631
Ondansetron OdtOndansetron13$331
Pregabalin25$251
Cyclobenzaprine Hcl21$135
Tizanidine Hcl22$113
Methocarbamol26$90
Levocetirizine Dihydrochloride11$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$278$19,86629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Clarksville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →